Antifosfolipid Sendromunda Doku Faktörü Düzeyi ve Doku Faktörü Promotor Bölge -603a/g Polimorfizminin Değerlendirilmesi

Yıl 2019, Cilt: 9 Sayı: 1, 1 - 6, 30.04.2019

Resul Kahraman Veysel Hancer Arzu Ergen Bedia Çakmakoğlu Reyhan Diz Küçükkaya

https://doi.org/10.26650/experimed.2019.19006

Öz

Anahtar Kelimeler

aPLA, antifosfolipid antikorlar, APS, antifosfolipid sendromu, TF, doku faktörü

Evaluation of Tissue Factor -603 A/G Promoter Gene Polymorphism in Thrombotic Processes in Patients with Antiphospholipid Syndrome

Öz

DOI:
10.26650/experimed.2019.19006

Objective: Major clinical manifestations of
Antiphospholipid syndrome (APS) are trombosis and thrombosis related
complications. Tissue factor (TF) serves primary initiatory of the in vivo
coagulation. TF gene expression may be induced in endothelial cells to initiate
thrombus formation. In this study, we investigated the frequency of TF 603A/G
promoter gene polymorphism in patients with antiphospholipid syndrome (APS) and
its effects on TF expression and thrombotic events.

Materials and Methods: This study included
64 patients with APS (APS patient with thrombosis arterial and venous (n=38),
antiphospholipid antibody-positive patients without thrombosis (n=26) and 44
healthy controls (HCs). Plasma TF levels and antiphospholipid antibodies were
measured by ELISA method. Lupus anticoagulant was measured by activated partial
thromboplastin time and kaolin clotting time. TF-603 A/G polymorphism was
investigated by PCR method.

Results: Our results have showed that
patients with APS, TF levels were found in patients significantly higher than
the healthy control group (p: 0.006, p<0.001, respectively). Compared
between the two patient groups, TF level was significantly higher in the
patient with thrombosis group compared to the patient without thrombosis group
(p: 0.027).

Conclusion: In this study, we suggest that
thrombotic complications observed in patients with APS are associated with
increased TF expression.

Cite this article as: Kahraman R, Hançer V,
Ergen A, Çakmakoğlu B, Diz Küçükkaya R. Evaluation of tissue factor -603 A/G
promoter gene polymorphism in thrombotic processes in patients with
antiphospholipid syndrome. Experimed 2019; 9(1): 1-6.

Anahtar Kelimeler

aPLA, antiphospholipid antibodies, APS, antiphospho­lipid syndrome, TF, tissue factor

Kaynakça

• 1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11. 2. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-32. 3. Atsumi T, Khamashta MA, Amengual O, Hughes GR. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222-3. 4. Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-41. 5. Reverter JC, Tàssies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free proteins. Arterioscler Thromb Vasc Biol 1996; 16: 1319-26. 6. McVey JH. Tissue factor pathway. Baillieres Clin Haematol 1994; 7: 469-84. 7. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-5. 8. Arnaud, E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, et al. Polymorphisms in the 5’ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l’Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol 2000; 20: 892-8. 9. Ilka Ott, Werner Koch, Nicolas von Beckerath, Rene de Waha, Anna Malawaniec, Julinda Mehilli, et al. Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis 2004; 177: 189-91. 10. Reny JL, Laurendeau I, Fontana P, Bieche I, Dupont A, Remones V, et al. The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost 2004; 91: 248-54. 11. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79; 276-81. 12. Dobado-Berrios PM, López-Pedrera C, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 1578-82. 13. Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J 2010; 8: 7.